Ovarian Cancer

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.

Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.

An oncology nurse, patient turned advocate and cancer biologist were honored during CURE®’s third annual Ovarian Cancer Heroes program where they got to share messages of resiliency with a virtual audience.

Time is a valuable commodity, especially for patients with cancer who may find themselves with limited time or limited free time to enjoy the things they loved prior to their cancer. But the COVID-19 pandemic is robbing patients of that precious time.

Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.

A weekly high dose of chemotherapy did not improve survival for patients with epithelial ovarian cancer, though the treatment regimen was effective and well-tolerated.

A proposed preventive surgery that would take out fallopian tubes before menopause but save ovary removal until afterwards was favored by most premenopausal previvors of ovarian cancer in a study.

The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.

Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.

The National Ovarian Cancer Coalition to host its annual "Together in Teal®" No Boundaries National Broadcast Celebration During September awareness month on Saturday, Septemeber 26, 2020.

Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.

Nearly half (48%) of the patients reported experiencing significant fatigue following their surgery. Thirty-nine percent of the patients still reported significant fatigue one year following their surgery.

Here is a list of the recent trial initiations that occurred within the cancer space in August.

While 75% of patients with gynecological cancers and COVID-19 will recover, new data from New York City shows specific risks for patients with cancer infected with COVID-19.

A roundup of the latest news and updates for patients with ovarian cancer from CURE®.

Although the study failed to meet its goal of progression-free survival, overall survival data are currently not yet available, and follow-up will continue until the next planned analysis.

Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.

A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.

Dr. Jubilee Brown discussed the use of telemedicine and oral treatment options for patients with ovarian cancer, as well as offered advice to ease stress and anxiety throughout the COVID-19 pandemic.

The combination of mirvetuximab soravtansine and Avastin (bevacizumab) demonstrated encouraging overall response rates in patients with ovarian cancer, regardless of the disease’s previous responsiveness to platinum-based chemotherapy, according to data presented at the 2020 ASCO Virtual Scientific Program.

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2020.

One survivor makes the most of the time in the infusion chair, creating beaded jewelry and helping herself and others to heal.

The Food and Drug Administration recently approved the combination of Lynparza (olaparib) and Avastin (bevacizumab) for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. Here’s what you need to know.

The Food and Drug Administration’s recent approval of Zejula is different from previous approvals as it is indicated for all patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, according to a gynecologic oncology expert.

Treatment with Lynparza in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin.

Understanding ovarian cancer.